The iFuse Bedrock Granite implant is designed for sacroiliac fusion and sacropelvic fixation and received the FDA’s breakthrough device designation, according to an April 19 news release.
Approval for the payment is subject to FDA clearance and finalization of the proposed rule. The CMS payment will help widen access to Medicare patients.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
